Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin
- 31 January 1997
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 36 (1), 19-28
- https://doi.org/10.1016/s0190-9622(97)70320-7
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biological studyBritish Journal of Dermatology, 1993
- Involvement of endogenously produced 1,25-dihydroxyvitamin D-3 in the growth and differentiation of human keratinocytesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1991
- 1,25(OH)2-D3 is a potent regulator of interleukin-1 induced interleukin-8 expression and productionBiochemical and Biophysical Research Communications, 1991
- Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgarisThe Lancet, 1991
- Localization of Neutrophil-Activating Peptide-1/Interleukin-8-Immunoreactivity in Normal and Psoriatic SkinJournal of Investigative Dermatology, 1991
- DNA content and Ks8.12 binding of the psoriatic lesion during treatment with the vitamin D3 nalogue MC903 and betamethasoneBritish Journal of Dermatology, 1990
- Mechanism of elongation of primed DNA by DNA polymerase delta, proliferating cell nuclear antigen, and activator 1.Proceedings of the National Academy of Sciences of the United States of America, 1990
- The immunobiology ofvitamin D: William F.C. RigbyImmunology Today, 1988
- A novel approach for the evaluation and treatment of psoriasis: Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasisJournal of the American Academy of Dermatology, 1988
- Vitamin D and Epidermal Differentiation: Evidence for a Role of Endogenously Produced Vitamin D Metabolites in Keratinocyte DifferentiationSkin Pharmacology and Physiology, 1988